Turner R B, Cetnarowski W E
Department of Pediatrics, Medical University of South Carolina, Charleston, SC 29425, USA.
Clin Infect Dis. 2000 Nov;31(5):1202-8. doi: 10.1086/317437. Epub 2000 Nov 6.
Two clinical trials were conducted, one involving 273 subjects with experimental rhinovirus colds and the other involving 281 subjects with natural colds. Symptomatic volunteers were randomized to receive oral lozenges containing zinc gluconate (13.3 mg), zinc acetate (5 or 11.5 mg), or placebo. The median duration of illness in zinc gluconate recipients was 2.5 days, contrasted with 3.5 days in the placebo recipients (P=.035), in the experimental colds study. Zinc gluconate had no effect on symptom severity and zinc acetate had no effect on either duration or severity. Neither formulation had an effect on the duration or severity of natural cold symptoms. Evaluation of blinding, taste, and adverse events revealed no significant differences among the 4 treatment arms. Zinc compounds appear to have little utility for common-cold treatment.
进行了两项临床试验，一项涉及273名患有实验性鼻病毒感冒的受试者，另一项涉及281名患有自然感冒的受试者。有症状的志愿者被随机分配接受含葡萄糖酸锌（13.3毫克）、醋酸锌（5或11.5毫克）的口服含片或安慰剂。在实验性感冒研究中，接受葡萄糖酸锌的受试者的疾病中位持续时间为2.5天，而接受安慰剂的受试者为3.5天（P = 0.035）。葡萄糖酸锌对症状严重程度没有影响，醋酸锌对持续时间或严重程度均无影响。两种制剂对自然感冒症状的持续时间或严重程度均无影响。对盲法、口味和不良事件的评估显示，四个治疗组之间没有显著差异。锌化合物似乎对普通感冒治疗几乎没有用处。
